<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03067129</url>
  </required_header>
  <id_info>
    <org_study_id>M16-123</org_study_id>
    <secondary_id>2016-004102-34</secondary_id>
    <nct_id>NCT03067129</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection</brief_title>
  <acronym>DORA</acronym>
  <official_title>An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label study to assess the pharmacokinetics (PK), safety, and efficacy of glecaprevir
      (GLE)/pibrentasvir (PIB) in pediatric participants divided into 4 age groups: 3 to &lt; 6, 6 to
      &lt; 9, 9 to &lt; 12, and 12 to &lt; 18 years of age. Within each age group, some participants will be
      enrolled for intensive pharmacokinetics (IPK) to characterize the PK of a particular age
      group and the remainder of participants will be enrolled for the evaluation of safety and
      efficacy of each age group. Intensive PK sampling is designed to allow for dose adjustment,
      based on available PK and clinical data to achieve therapeutic exposures that have been safe
      and efficacious in adults.

      Part 1 of the study will enroll participants into Cohort 1; Cohort 1 will include
      participants who are in 12 to &lt; 18 years of age who can swallow the adult formulation of
      GLE/PIB. Part 2 of the study will enroll participants in the remaining age groups into
      Cohorts 2, 3, and 4; participants in these cohorts will receive the pediatric formulation of
      GLE/PIB. All participants will receive GLE/PIB for 8, 12, or 16 weeks depending on their
      hepatitis C virus (HCV) genotype, cirrhosis, and prior treatment experience status.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 20, 2017</start_date>
  <completion_date type="Anticipated">November 21, 2022</completion_date>
  <primary_completion_date type="Actual">February 18, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve (AUC) of Glecaprevir (GLE)</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>The area under the plasma concentration-time curve (AUC) is a method of measurement of the total exposure of a drug in blood plasma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of Pibrentasvir (PIB)</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>The area under the plasma concentration-time curve (AUC) is a method of measurement of the total exposure of a drug in blood plasma.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with post-treatment HCV virologic relapse</measure>
    <time_frame>Up to 160 weeks after first dose of study drug</time_frame>
    <description>Post-treatment relapse is defined as confirmed HCV RNA greater than or equal to the LLOQ between end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment as planned with HCV RNA less than LLOQ at the end of treatment; excluding participants who have been shown to be re-infected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with new HCV infection at any time up to the last study visit</measure>
    <time_frame>Up to 160 weeks after first dose of study drug</time_frame>
    <description>Participants with new HCV infection at any time up to the last study visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance of GLE</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Clearance is defined the volume of plasma cleared of the drug per unit time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants who experience on-treatment virologic failure (i.e., breakthrough or fail to suppress at the end of treatment)</measure>
    <time_frame>Up to 160 weeks after first dose of study drug</time_frame>
    <description>Virologic failure defined as confirmed increase of greater than 1 log10 IU/mL above nadir during treatment, confirmed HCV RNA greater than or equal to 100 IU/mL after HCV RNA less than LLOQ during treatment, or HCV RNA greater than or equal to LLOQ at the end of treatment with at least 6 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of PIB</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Maximum observed plasma concentration (Cmax) of PIB after administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance of PIB</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Clearance is defined the volume of plasma cleared of the drug per unit time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with sustained virologic response 12 weeks post dosing (SVR12)</measure>
    <time_frame>12 weeks after last dose of study drug</time_frame>
    <description>SVR12 is defined as hepatitis C virus ribonucleic acid (HCV RNA) levels less than the lower limit of quantitation (LLOQ) (less than 15 IU/mL) 12 weeks after the last actual dose of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of GLE</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <description>Maximum observed plasma concentration (Cmax) of GLE after administration.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">129</enrollment>
  <condition>Hepatitis C Virus (HCV)</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Adult formulation GLE/PIB subjects 12 to &lt; 18yrs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1: Adult formulation Glecaprevir (GLE)/Pibrentasvir (PIB) 300 mg/120 mg once daily (QD) for 8, 12, or 16 weeks depending on their hepatitis C virus (HCV) genotype, cirrhosis status, and prior treatment experience in participants 12 to &lt; 18 years of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: Pediatric formulation GLE/PIB subjects 3 to &lt; 6yrs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 4: Pediatric formulation GLE/PIB for 8, 12, or 16 weeks depending on their HCV genotype, cirrhosis status, and prior treatment experience in participants 3 to &lt; 6 years of age. Formulation details on GLE/PIB to be provided as part of a study protocol amendment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Pediatric formulation GLE/PIB subjects 6 to &lt; 9yrs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 3: Pediatric formulation GLE/PIB for 8, 12, or 16 weeks depending on their HCV genotype, cirrhosis status, and prior treatment experience in participants 6 to &lt; 9 years of age. Formulation details on GLE/PIB to be provided as part of a study protocol amendment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Pediatric formulation GLE/PIB subjects 9 to &lt; 12yrs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2: Pediatric formulation GLE/PIB for 8, 12, or 16 weeks depending on their HCV genotype, cirrhosis status, and prior treatment experience in participants 9 to &lt; 12 years of age. Formulation details on GLE/PIB to be provided as part of a study protocol amendment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glecaprevir/Pibrentasvir</intervention_name>
    <description>Film-coated tablet (100 mg/40 mg)</description>
    <arm_group_label>Cohort 1: Adult formulation GLE/PIB subjects 12 to &lt; 18yrs</arm_group_label>
    <other_name>ABT-493/ABT-530</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glecaprevir/Pibrentasvir</intervention_name>
    <description>Oral pediatric formulation</description>
    <arm_group_label>Cohort 2: Pediatric formulation GLE/PIB subjects 9 to &lt; 12yrs</arm_group_label>
    <arm_group_label>Cohort 3: Pediatric formulation GLE/PIB subjects 6 to &lt; 9yrs</arm_group_label>
    <arm_group_label>Cohort 4: Pediatric formulation GLE/PIB subjects 3 to &lt; 6yrs</arm_group_label>
    <other_name>ABT-493/ABT-530</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hepatitis C virus (HCV) infection demonstrated by positive anti-HCV antibody (Ab) and
             HCV Ribonucleic acid (RNA) greater than or equal to 1000 IU/ mL.

          -  Subject must have a weight consistent with a recommended weight range for their age at
             the time of screening.

        Exclusion Criteria:

          -  Females who are pregnant or breastfeeding.

          -  Positive test result for Hepatitis B surface antigen (HbsAg) or positive test result
             for HBV DNA.

          -  Participants with other known liver diseases.

          -  Decompensated cirrhosis defined as: presence of ascites, history of variceal bleeding,
             lab values consistent with Child's class B or C cirrhosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Univ of California San Francis /ID# 158002</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital Colorado /ID# 157996</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CT Childrens Medical Ctr, US /ID# 158639</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UF Hepatology Research at CTRB /ID# 158008</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610-0272</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital /ID# 166022</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University /ID# 158001</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Childrens Hospital /ID# 157988</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center /ID# 157997</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia Univ Medical Center /ID# 158000</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032-3725</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC Health Care /ID# 157991</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Childrens Hosp Med /ID# 158007</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hosp Philadelphia /ID# 158003</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Child Hosp of Pittsburgh,PA /ID# 158004</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213-2583</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monroe-Carell Jr. Children's H /ID# 169037</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine /ID# 157989</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-3411</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint Luc /ID# 162173</name>
      <address>
        <city>Woluwe-Saint-Lambert</city>
        <state>Bruxelles-Capitale</state>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven /ID# 162174</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alberta Children's Hospital /ID# 163449</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B 6A9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stollery Children's Hospital /ID# 163450</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children /ID# 163448</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Freiburg /ID# 165187</name>
      <address>
        <city>Freiburg im Breisgau</city>
        <state>Baden-Wuerttemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Universitatsmedizin Berlin Campus Virchow Klinikum /ID# 165186</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Wuppertal /ID# 165185</name>
      <address>
        <city>Wuppertal</city>
        <zip>42283</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kurume University Hospital /ID# 165718</name>
      <address>
        <city>Kurume-shi</city>
        <state>Fukuoka</state>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital /ID# 165709</name>
      <address>
        <city>Suita-shi</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juntendo University Hospital /ID# 212912</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8431</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka General Medical Center /ID# 212745</name>
      <address>
        <city>Osaka</city>
        <zip>558-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Jorge Children Hospital /ID# 160850</name>
      <address>
        <city>San Juan</city>
        <zip>00912-3310</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Institution - Institute of Nutrition /ID# 163345</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>109240</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Medical Scientific Centre of children health /ID# 163344</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>119296</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scientific and Research Institute of pediatric infections /ID# 163343</name>
      <address>
        <city>Saint-petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Univ Vall d'Hebron /ID# 163323</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Deu /ID# 163282</name>
      <address>
        <city>Esplugues de Llobregat</city>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz /ID# 163283</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp Univ Politecnico la Fe /ID# 163325</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingham Childrens Hospital /ID# 162718</name>
      <address>
        <city>Birmingham</city>
        <zip>B4 6NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth University Hos /ID# 162719</name>
      <address>
        <city>Glasgow</city>
        <zip>G514TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital NHS /ID# 162717</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>Puerto Rico</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 24, 2017</study_first_submitted>
  <study_first_submitted_qc>February 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2017</study_first_posted>
  <last_update_submitted>June 9, 2020</last_update_submitted>
  <last_update_submitted_qc>June 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Hepatitis C Virus</keyword>
  <keyword>Glecaprevir</keyword>
  <keyword>Pibrentasvir</keyword>
  <keyword>Pharmacokinetic</keyword>
  <keyword>Treatment naïve</keyword>
  <keyword>Treatment experienced</keyword>
  <keyword>Interferon (IFN)</keyword>
  <keyword>pegylated interferon (pegIFN)</keyword>
  <keyword>Ribavirin (RBV)</keyword>
  <keyword>sofosbuvir</keyword>
  <keyword>Non-cirrhotic cirrhosis</keyword>
  <keyword>Compensated (Child-Pugh A) cirrhosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

